88 - Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Baseline Blood Pressure Categories: LEADER and SUSTAIN 6

High blood pressure (BP) is prevalent in patients with type 2 diabetes (T2D). This posthoc analysis evaluated major adverse cardiovascular events (MACE) and renal events in patients with T2D and high cardiovascular (CV) risk who received liraglutide or semaglutide, with data analyzed according to BP categories (mmHg): normal (<120/80), elevated (systolic ≥120—<130 and diastolic <80), stage 1 hypertension (systolic ≥130—<140 or diastolic ≥80—<90)...